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Retroviral DNA integration into the host genome is
mediated by nucleoprotein assemblies containing
tetramers of viral integrase (IN). Whereas the fully
active form of IN comprises a dimer of dimers, the
molecular basis of IN multimerization has not been
fully characterized. IN has consistently been crystal-
lized in an analogous dimeric form in all crystallo-
graphic structures and experimental evidence as to
the level of similarity between IN monomeric and
dimeric conformations is missing because of the
lack of IN monomeric structures. Here we identify
Phe187 as a critical dimerization determinant of IN
from feline immunodeficiency virus (FIV), a nonpri-
mate lentivirus that causes AIDS in the natural host,
and report, in addition to a canonical dimeric struc-
ture of the FIV IN core-domain, a monomeric struc-
ture revealing the preservation of the backbone
structure between the twomultimeric forms and sug-
gest a role for Phe187 in ‘‘hinging’’ the flexible IN
dimer.
INTRODUCTION
Integrase (IN) of the human immunodeficiency virus-1 (HIV-1)
mediates the integration of viral DNA into the host genome dur-
ing the viral life cycle and thus has been targeted in anti-HIV
research and AIDS (Krishnan and Engelman, 2012). IN cleaves
a dinucleotide from each 30-end of the reverse-transcribed viral
double-stranded DNA, in a process termed 30-processing, to
prepare the DNA for integration into the host genome in a conse-
quent second step termed strand transfer, the latter step being
the target of the current IN strand transfer inhibitors (INSTIs;
Krishnan and Engelman, 2012).
Like HIV-1 and other retroviral INs, the feline immunodefi-
ciency virus (FIV) IN functions as a multimer, in which discrete
domains from each protomer functionally complement each
other, and it contains the three common functional domains:
the N-terminal domain (NTD) containing the ‘‘HH-CC’’ zinc-bind-
ing motif, the catalytic core (CCD) including the canonical cata-
lytic triad D66D118E154, and the C-terminal domain (CTD) with
an SH3-like fold (Figure 1A; Jaskolski et al., 2009; Li et al.,1512 Structure 22, 1512–1519, October 7, 2014 ª2014 Elsevier Ltd A2011; Shibagaki et al., 1997). The high sequence conservation
between the IN CCD domains of FIV and HIV-1 (44% identity)
suggested the FIV IN CCD structure and INSTIs binding site
would be nearly the same as for HIV IN; a prediction that has
been validated by the effective binding of INSTIs to FIV and the
inhibition of FIV replication by INSTIs in vitro at concentrations
comparable to those reported for HIV-1 (Savarino et al., 2007).
The seminal structures of IN-DNA complexes from prototype
foamy virus (PFV) provided the groundbreaking structural details
for IN oligomeric organization within the functional IN-DNA inte-
gration complexes, confirming the critical tetrameric state of
assembly (Hare et al., 2010; Maertens et al., 2010). Tetramers
comprise a dimer of dimers, where the individual dimers pre-
serve a common CCD-CCD dimerization interface, and each
dimer is required to bind to one of the viral DNA ends. Whereas
the fully active form of IN is evidently a tetramer, various other
oligomeric states, including monomers and dimers, do exist in
solution and the correct precursors in the tetramer assembly
pathway are yet to be determined (Alian et al., 2009; Bojja
et al., 2013; Hare et al., 2010; Lesbats et al., 2008; Li et al.,
2006; Maertens et al., 2010; Pandey et al., 2011).
Diverse models for dimeric and multimeric assemblies, partic-
ularly distinctive between IN unbound (apo) and DNA-bound
forms, have been proposed (Alian et al., 2009; Ballandras
et al., 2011; Barsov et al., 1996; Johnson et al., 2013; Krishnan
et al., 2010; Lesbats et al., 2008; Yin and Craigie, 2010). A
‘‘reaching dimer’’ configuration of the apo-IN has been reported
lacking the canonical CCD-CCD interface and is stabilized
mainly by CTD-CTD interactions (Bojja et al., 2013), a variation
that presumably affects global protein structure by affecting
the relative positions of the individual domains (Maillot et al.,
2013).
The principal role of CCD in IN dimerization is well recognized,
most remarkably by its consistent crystallization in an analogous
dimeric form in all crystallographic structures (Jaskolski et al.,
2009; Li et al., 2011; except for one slightly variant dimeric
configuration, Ballandras et al., 2011). Experimental evidence
as to the level of similarity between IN monomeric and dimeric
conformations is missing because of the lack of IN structures
in its monomeric form. The canonical CCD-CCD dimer interface
has been shown to predominantly involve hydrophobic contacts
among a1, a5, and a6 (Jaskolski et al., 2009; Serrao et al., 2012).
Notably, all available crystal structures of retroviral IN CCD, in
either single or two-domain constructs, contain a linker region
(residues 191–210 in HIV-1 IN) and no construct comprising
the CCD alone (52–190 in HIV-1 IN) has been crystallized. Thisll rights reserved
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Figure 1. Domain Organization and Size Exclusion Chromatography Analysis of FIV and HIV-1 IN Variants
(A) Schematic representation of the various FIV IN variants used. FL: full length (1–281); CCD: catalytic core domain of two variants: short (S; 61–188) and
extended (E; 61–212); C-NTD: N-terminal-core two-domain (1–188), C-CTD: C-terminal-core two-domain (61–281). Theoretical molecular weights (kDa) of FIV
and HIV-1 variants are shown (right).
(B) SEC analysis of short (fiv-S) and extended (fiv-E) variants of F187Kmutant CCD fromFIV andHIV-1 (hiv-S: 52–186; hiv-E: 52–210), andWTFIV CCD (fiv-E-WT).
(C) SEC analysis of full-length FIV IN WT (fiv-FL) and F187K mutant (fiv-FL-F187K) compared to F185K mutant of full-length HIV-1 IN (hiv-FL).
(D) SEC analysis of WT FIV C-CTD, and F187K mutants of C-CTD (C-CTD-F187K) and C-NTD (C-NTD-F187K). Molecular mass markers (sizes in kilodaltons) are
shown in gray. Insets: apparent molecular masses of corresponding peaks as determined by partition coefficient [Kav = (elution volume  void volume) / (total
volume  void volume)].
(E) In vitro 30-processing activities of WT full-length FIV IN and F187K mutant as compared to control containing DNA without IN (Ctrl). Error bars represent SD of
three independent replicates.
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Monomeric Structure of Retroviral Integraseis probably because, in addition to practicality and convenience
in construct preparations (Jaskolski et al., 2009), the region link-
ing the CCD to CTD (C-terminal linker [CTL]) was found, unlike
the NTD and CTD, to function in cis to the CCD (Engelman
et al., 1993; Shibagaki et al., 1997). Functional importance of res-
idue composition, and finger flexibility, of the CTL region (186–
196 from HIV-1 IN) has been implicated in viral infectivity and
in IN functional tetramerization, nuclear localization, enzymatic
activities, and conformational changes upon DNA binding (Ber-
thoux et al., 2007; Cellier et al., 2013; Hare et al., 2009a; ZhaoStructure 22, 1512–et al., 2008). Still, if the CTL plays a crucial role in the formation
of IN dimers, the precursors of functional tetramers, it remains
to be clarified.
To foster our understanding of IN multimerization, particularly
to highlight common and distinct features in the dimerization
process, we investigated dimerization of IN using an FIV model
system. The FIV model has greatly advanced our understanding
of several basic questions in retrovirology (e.g., nuclear import,
two-receptor entrance, replication in non-dividing cells, spe-
cies-specificity, and broad-based inhibitor studies) and can1519, October 7, 2014 ª2014 Elsevier Ltd All rights reserved 1513
Table 1. Data Collection and Refinement Statistics
Monomeric CCD Dimeric CCD
Data Collection
Space group P 21 P6522
Mol/ASU Cell
dimensions
1 1
a, b, c (A˚) 28.25, 66.64, 32.62 52.92, 52.92, 193.57
a, b, g () 90.00, 103.43, 90.00 90.00, 90.00, 120.00
Resolution (A˚)a 33.32–1.08 (1.118–1.08) 45.83–1.84 (1.91–1.844)
Rsym or Rmerge 0.03683 (0.4863) 0.09952 (0.3539)
I/sI 15.94 (2.28) 29.66 (6.74)
Completeness (%) 95.5 (88.4) 90.6 (88.2)
Redundancy 3.4 (3.3) 15.2 (13.8)
Refinement
Resolution (A˚) 1.1 1.84
No. unique
reflections
48,083 (4402) 13,341 (1263)
Rwork/Rfree (5%) 0.140/0.176 0.185/0.225
No. atoms
Protein 1,195 1,188
Water 186 111
B-factors
Protein 14.0 25.4
Water 33.9 38.5
Rmsds
Bond lengths (A˚) 0.02 0.018
Bond angles () 1.94 1.82
Ramachandran (%)
Favored 100 100
Outliers 0 0
PDB code 4MQ3 4PA1
aNumber in parentheses is for highest resolution shell.
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lentivirus is used to infect its natural, inexpensive and uncontro-
versial host (Bienzle, 2014). We found that a single F187K muta-
tion, analogous to the commonly used F185K solubility mutation
in HIV-1 IN (Jaskolski et al., 2009) monomerizes an otherwise
dimeric FIV IN, an exciting finding that we further exploited to
obtain a crystal structure of IN CCD in the monomeric form,
providing experimental evidence for the preservation of the IN
CCD backbone between monomeric and canonical dimeric
forms.
RESULTS AND DISCUSSION
Phe187 Is Essential for FIV IN Dimerization
Unlike HIV-1 IN for which the CCD (52–210, F185K) exists in the
dimeric state, the FIV IN CCD (61–188, F187K) exists as mono-
mers (Figure 1B). Because the FIV IN CCD construct used here
lacks the C-terminal linker region (CTL, residues 189–212 in
FIV (Figure 1A) and 191–210 in HIV-1 INs), which is present in
all reported IN CCD structures, we investigated whether CTL
absence caused the observed monomeric state. Thus, we1514 Structure 22, 1512–1519, October 7, 2014 ª2014 Elsevier Ltd Aextended the FIV IN CCD to comprise residues 61-212 and, in
parallel, truncated HIV-1 IN CCD to contain only 52–186. The re-
sults clearly reveal that themultimerization state of either IN CCD
is not affected by the presence or absence of the CTL fragment
(Figure 1B). This suggests that the CTL, which is known to func-
tion in cis to CCD (Engelman et al., 1993; Shibagaki et al., 1997)
and to critically mediate functional IN tetamerization and activity
(Cellier et al., 2013; Hare et al., 2009a), does not seem to play a
crucial role in dimerization (at least in absence of DNA sub-
strates). Similarly, Lys188 (analogs to HIV-1 K186 that has
been implicated in HIV-1 IN multimerization; Berthoux et al.,
2007) does not participate in the dimerization of IN because
the addition of CTL (containing wild-type [WT] K188) to F187K
mutant constructs did not induce dimerization (Figure 1).
Lys188 indeed has been shown to stabilize the tetrameric form
of IN by interactions with the NTD of the other dimer (Berthoux
et al., 2007; Hare et al., 2009a). To further clarify the location of
the dimerization determinants of FIV IN, which are apparently
distinct from those of HIV-1 IN, we characterized the oligomeric
states of full-length FIV IN and truncation variants containing the
CCD fused to either CTD (C-CTD) or NTD (C-NTD; Figure 1A).
Unlike HIV-1 IN for which the full-length protein exists predomi-
nantly in the tetrameric state (Alian et al., 2009; Figure 1C), WT
full-length FIV IN exists predominantly in the dimeric form and
its F187K variant in the monomeric state (Figure 1C). Similarly,
WT C-CTD (residues 61–281) exists as dimers whereas the intro-
duction of F187K into this C-CTD construct rendered it mono-
meric (Figure 1D). Notably, a Y244A/W245A double mutation
within the SH3-like domain, known to disrupt the reaching-dimer
configuration in HIV-1 IN (Bojja et al., 2013), did not disrupt the
dimeric form of the FIV CCD-CTD. Likewise, the addition of the
NTD (residues 1–60) to the F187K variant of CCD (C-NTD,
1–188) was insufficient to induce its dimerization (Figure 1D).
Consistently, in all variants analyzed, WT FIV IN exists as dimers
whereas a single F187K mutation, analogous to the common
F185K solubility mutation in HIV-1 IN, disrupts the dimeric inter-
action, leading to the formation of monomers. Thus, WT IN of FIV
is soluble and stable in its unbound state without a Lys/His sol-
ubility mutation at position 187 (185 in HIV-1/2 INs) and its
F187K is highly soluble and stable in the monomeric form and
at high concentrations.
The F187K mutant of full-length IN has been found competent
for 30-processing activity performing the cleavage reaction at
comparable levels to the WT (Figure 1E), implying that F187K
mutation does not affect the integrity of the CCD fold. Although
this may indicate that monomers of FIV IN can catalyze 30-pro-
cessing, unlike all other characterized retroviral INs that report-
edly require protein multimerization (Engelman et al., 1993;
Faure et al., 2005; Fletcher et al., 1997), we cannot precludemul-
timer assembly upon DNA binding, particularly since FIV IN has
also been shown to function in multimers (Shibagaki et al., 1997).
Thus, the biological significance of the F187K mutation can best
be revealed in activities that critically require the dimerization of
IN such as in vitro strand transfer or in vivo pre-integration com-
plex assembly and viral replication. Intriguingly, unlike HIV IN, re-
combinant FIV IN has been reported inefficient for in vitro strand
transfer activity (Vink et al., 1994), a result that we have also
confirmed (data not shown). It will be interesting to investigate
this feature of FIV IN that may highlight additional requirementsll rights reserved
Figure 2. FIV IN CCD Structures
(A) Superposition of canonical dimeric forms of IN CCD from FIV (orange/yellow) and HIV-1 (magenta/violet, 1BIS, rmsd: 0.97 A˚).
(B) CCD P21 unit cell representation with a top-view along b-axis (left) and side view (b-axis is labeled). a Helices are numbered and D66-Ca (catalytic-site) is
represented by a sphere (marked with red asterisk).
(C) Structural superposition of IN CCD from FIV (red), HIV-1 (magenta, 1BL3, rmsd: 1.13 A˚), PFV (blue, 3L2V, rmsd: 0.96 A˚), and RSV (yellow, 1C1A, rmsd: 1.13 A˚).
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Monomeric Structure of Retroviral Integrasefor the integration step of FIV perhaps elucidating alternative
pathways to those used by HIV. The effects of F187K on pre-
integration complex assembly and cellular localization and on
viral replication are currently being characterized.
Crystal Structure of FIV IN CCD in the Monomeric Form
Reveals Backbone Structural Preservation between
Monomeric and Dimeric Forms
Given that IN CCD is readily crystallizable (Jaskolski et al., 2009),
and isolation of FIV IN in two distinct mulitmeric forms, dimer
(WT) and monomer (F187K), provided a unique opportunity to
further analyze the molecular details of the integrase core
domain in monomeric form and compare this to the dimeric
form. Indeed soluble and stable monomeric (61–188, F187K)
and dimeric (61–212, WT) FIV IN CCD readily crystallized, with
the monomeric form giving the highest reported resolution of
any lentiviral IN to date (1.1 A˚). Both constructs crystallized
with one molecule per asymmetric unit in the P21 and P6522
space groups, respectively (Table 1) and, as expected, the
crystal structure from the dimeric solution of CCD formed the
canonical dimer with a symmetry-related molecule in crystal
(Figure 2A). However, symmetry-related molecules from the
monomeric form crystals failed to produce dimers (Figure 2B),
providing a crystal structure of IN CCD in the monomeric
configuration.
The overall backbone structures of the two FIV IN CCD
forms are nearly identical to each other (root-mean-square
deviation [rmsd] 0.8 A˚) and to that of other dimeric crystal
structures from lentiviruses (e.g HIV-1) and retroviruses
(e.g., Rous sarcoma retrovirus [RSV] and PFV; Figure 2C).
This provides experimental evidence for preservation of the
IN CCD backbone between monomeric and canonical dimeric
forms; a result especially important in validating the use of
single IN chains extracted from dimeric crystal structures for
molecular dynamics simulation studies and in silico identifica-
tion and development of IN anti-dimerization inhibitors (Al-
Mawsawi et al., 2006; Sippel and Sotriffer, 2010; Tintori et al.,
2012).Structure 22, 1512–The Catalytic Loop Is Fully Structured in a ‘‘Closed’’
Conformation
In both the monomeric and dimeric FIV IN CCD structures,
the catalytic-loop (residues 142–155) is fully structured and
folded toward the catalytic site in a ‘‘closed’’ conformation
comparable to that observed in PFV IN-DNA intasome or in
unbound RSV IN (Figure 2C). The loop retained this exact
conformation whether monomeric CCD was crystallized at
pH 5.5 or 8.5 (see Experimental Procedures), with only Asp66
in the catalytic triad occupying a different conformation at
the different pHs (Figure 3A). Of note, dimeric CCD that
was crystallized under different conditions (see Experimental
Procedures) yielded an unstructured loop similar to that of
previously determined IN CCD dimeric structures. Modeling
reveals that whereas the loop in the closed conformation
would not clash with viral DNA (Figure 3B), a conserved P144
residue (HIV-1 P142, PFV P211) would clash with host
acceptor-DNA and inhibitors mandating loop movement to
enable substrate binding (Figure 3C). In FIV, the shallower
cavity formed by the backbone of smaller G145 (Y212 in PFV
and Y143 in HIV-1) apparently provides sufficient space for
binding of INSTI because raltegravir binds and inhibits FIV IN
at concentrations comparable to those used with HIV-1 IN
(Savarino et al., 2007).
Possible Role of Phe187 in Hinging the Flexible IN Dimer
The backbone of Lys187 (and following Lys188) in the mono-
meric FIV IN CCD adopts a different conformation than the
equivalent residues in all other retroviral IN dimeric structures
(including the conformation of native Phe187 from the dimeric
FIV IN CCD structure and the reported Phe185 of HIV-2; Hare
et al., 2009b; Figure 4A). This could be due to the absence of
an opposite protomer as a binding partner or due to the lack of
the CTL extension to force a canonical conformation. Still, the
extension of CCD with CTL fragment (61–212, F187K) was not
sufficient to induce dimerization (Figure 1B). Except for residue
187 (and following 188), the conformation of the residues at the
dimeric interface is mostly invariant between the monomeric1519, October 7, 2014 ª2014 Elsevier Ltd All rights reserved 1515
Figure 3. FIV IN CCD Loop Structure and
Modeling
(A) Stereo view (wall-eyed) of the catalytic-site loop
from monomeric CCD with FO-FC map (3.0 s)
calculated with residues 142–155 omitted. D66
conformations at pH 8.5 (blue omit-map) and pH
5.5 (green omit-map and blue stickball) are shown.
(B) Modeling of FIV IN-DNA complex. Original
crystal-conformation of the catalytic loop (red) is
modeled with viral DNA based on 3L2R. Catalytic
triad is labeled and represented with green lines
(FIV) or blue stickballs (PFV). P144 from FIV is
labeled and shown in green stickballs. The catalytic
loop of PFV IN is presented with transparent blue
cartoon. Green sphere represents Mg2+ ion.
(C) Modeling of FIV IN-DNA-INSTI complex. Amino
acid sequence of FIV IN CCD was homology
modeled to fit PFV intasome-raltegravir structure
(3L2V). Variant residues in PFV IN (blue lines) and
FIV IN (green lines) are Q186/N119; T210/I143;
S209/G142; Y212/G145; H213/N146; S217/Q150.
Blue spheres represent Mn2+ ions from 3L2V.
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Monomeric Structure of Retroviral Integraseand dimeric forms, thus accentuating the critical contribution of
Phe187 to the dimerization of FIV IN.
Several residues at the CCD-CCD canonical dimer interface,
implicated as critical for HIV-1 IN dimerization (Serrao et al.,
2012), are dissimilar in FIV IN but also in the other retroviral INs
(Figure 4B, blue highlights). The HIV-1 IN CCD (52–210) dimer
interface buries 25% more area than FIV IN CCD (61–212;
1,500 A˚2 versus 1,200 A˚2) and involves twice as many hydropho-
bic contacts (99 versus 43), explaining the susceptibility of FIV
IN, but not HIV-1, tomonomerization by a single F187Kmutation.
It is well recognized that the tetrameric configuration of apo-IN is
dissimilar to that of IN assembled upon DNA binding, and that IN
must exist in lower-order oligomeric states in order to interact
with the substrate DNA and form functional intasomes (Alian
et al., 2009; Barsov et al., 1996; Bojja et al., 2013; Lesbats
et al., 2008).Whereas the form of these smaller-multimeric IN en-
tities, likely dimers, and their interaction interfaces and assembly
pathways are yet to be defined, we suggest that the residue at
the C-terminal tip of CCD a-5 (F187 in FIV) may pin the dimer
interface, which hinges the two protomers together during flex-
ible IN rearrangements upon DNA binding. Such a pivot at resi-1516 Structure 22, 1512–1519, October 7, 2014 ª2014 Elsevier Ltd All rights reserveddue N255 (equivalent to F187 in FIV) is
noticeable in the CCD dimeric interface
of PFV IN that, upon DNA binding, opens
up by 11 A˚ at the N terminus of CCD
a-helix-5 and exposes 50% of the buried
area (reducing the 1,600 A˚2 in apo-IN
[3DLR] to 870 A˚2 in IN-DNA [3L2V]; Fig-
ure 4C). Integrity and flexibility of the
dimeric interface around this hinge has
been implicated in IN multimerization and
catalytic activities (Berthoux et al., 2007;
Cellier et al., 2013; Hare et al., 2009a).
The finding that dimerization of FIV IN
can be abrogated by a single amino acid
substitution (F187) further validates the
proposed strategy for inhibiting protein-protein interactions by targeting ‘‘functional epitopes’’ or
‘‘hot spots’’ (few residues) at the interacting interfaces, once
confined, rather than targeting the entire interacting surfaces
(Sippel and Sotriffer, 2010; Toogood, 2002).
In conclusion, we report structures of FIV IN; the catalytic
core-domain crystallized in the usually obtained dimeric form
along with a monomeric form. The monomeric structure ob-
tained from stable monomeric IN in solution finally validates
the backbone preservation of IN core-domain between the
monomeric and dimeric structures reported here, and reveals
that dimerization of FIV IN relies on a single amino acid
(Phe187); a result that not only can challenge our current under-
standing of IN dimerization, but can also facilitate in vivo func-
tional studies with IN-F187K mutant FIV virus and assaying for
viral replication and infectivity, IN multimerization and interaction
with host proteins (e.g., LEDGF), preintegration complex forma-
tion, nuclear localization, and integration. The FIV model is espe-
cially suitable for such studies because its biology and disease
in cats are common with those of HIV in human and can be
used to advance anti-AIDS studies. We propose exploiting the
FIV IN as a model system for future in vitro and in vivo efforts
Figure 4. FIV IN CCD Sequence and Structural Comparisons and the Proposed Dimer Hinging Model
(A) F187K (red stick) of monomeric FIV CCD superposed to the WT dimeric structure (two protomers in yellow and in orange showing F187, in orange stick, with
FO-FCmap [3.0 s] calculated while omitting residue F187 [blue map] or F187K [magenta map]); HIV-2 WT F185 (magenta line, 3F9K) and HIV-1 F185K and K186
(cyan lines, 1BIS). Lys188 of FIV CCD is also shown in line-representation for monomeric (red) and dimeric (orange) forms. Helices a1 and a5 are labeled.
(B) Sequence alignment of IN CCD from various retroviruses. Conserved residues are white on a red background, and conservative substitutions are red on a
white background. Catalytic triad D-D-E residues are labeled with red asterisks. Dissimilar residues at the dimer interface are highlighted with blue. Secondary
structure elements from FIV and HIV-1 (1BIS) are shown (blue) above and below their sequences, respectively (coil, helix; arrow, b strand; T, turn).
(C) Dimers of PFV IN in apo (3DLR, pale-blue) and DNA bound forms (3L2V, marine-blue) are shown from side view (left). Blue dashed arrow indicates CCD
displacement of11 A˚ upon DNA binding (at A188 of a5 distal end). Inset represents an enlargement of the ‘‘hinge’’ interface comparing open and closed dimers.
Interacting residues are shown with sticks; distances in angstroms are indicated with red dashed lines. The PFV IN a helix5 N255 (analogous to F187 of FIV IN)
interaction with the backbone oxygen of a helix1 I176 and S175 from the opposite protomer remains constant, 9 A˚ distance, for both apo (closed) and DNA-
bound (open) forms.
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Monomeric Structure of Retroviral Integraseparticularly aimed at understanding the molecular basis of IN
multimerization and the assembly pathways of functional inte-
gration complexes.EXPERIMENTAL PROCEDURES
Protein Preparation
IN variants of FIV (Petaluma; a gift from Prof. Carsten Mu¨nk, Germany) were
subcloned into pET28b (Novagen) with a cleavable His-tag. Wild-type full
length and C-CTD two-domain constructs contain a C274S mutation. HIV-1
IN CCD constructs were derived from the previously described HIV-1 IN
(SF1; C56S, W131D, F185K, and C280S; Alian et al., 2009). Mutations were
introduced using QuikChange Kit (Agilent Technologies Genomics). IN con-
structs were expressed and purified as previously described (Alian et al.,
2009). Protein solutions contain 20 mM HEPES pH 7.4, 1 mM dithiothreitol,
1 M NaCl for full-length or 0.5 M NaCl for the truncation variants, and 1 mM
CHAPS for CTD-containing constructs. Apparent molecular masses wereStructure 22, 1512–analyzed on a Superose-12 column (GE Healthcare Life Sciences) as
compared to molecular size standards (Bio-Rad).
Protein Crystallization, Data Collection, and Structure
Determination
FIV IN CCD (WT 61–212 or F187K 61–188, at 8–9 mg/ml with 1 mM MgCl2)
crystals were grown (20C) using the hanging-drop vapor-diffusion method.
Diffracting crystals of monomeric CCD (61–188, F187K) were readily obtained
in various sparse-matrix screen conditions: ProComplex-A4, Classics-H11
and H6, PEGs-B5, B11 and B11, JCSG-G1, G4, H10, and H8. Crystals of
the monomeric form (from JCSG-G4: 0.2 M trimethylamine N-oxide, 0.1 M
Tris-HCl pH 8.5, 20% [w/v] PEG-MME-2000) were used for data collection
and structure determination in P21 space group with one molecule per asym-
metric unit (Table 1). The alternative conformation of Asp66 was revealed in
crystals grown at pH 5.5 in JCSG-H8 (0.2 M NaCl, 0.1 M Bis-Tris pH 5.5,
25% PEG 3350), which also diffracted to 1.1 A˚. Diffraction quality crystals of
the dimeric CCD (CCD-E, 61–212) were readily obtained in two conditions:
anions-B7 (2.5 M sodium acetate, 0.1M Tris-HCl pH 8.5) with P31 space1519, October 7, 2014 ª2014 Elsevier Ltd All rights reserved 1517
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Monomeric Structure of Retroviral Integrasegroup and two molecules per asymmetric unit and unstructured catalytic loop
(not shown), and classics-H4 (30% [w/v] PEG-4000, 0.2 M MgCl2, 0.1 M Tris-
HCl pH 8.5) resulting in P6522 space group with one molecule per asymmetric
unit (Table 1). Cryogenic solutions contained a supplement of 20% (v/v)
glycerol.
Diffraction data for monomeric CCD (61–188, F187K) were collected at
beamline 14.1 of BESSY-II synchrotron (Helmholtz-Zentrum Berlin), and pro-
cessed with XDSAPP (Krug et al., 2012). Diffraction data for dimeric CCD
(61–212) were collected in-house on a Rigaku FR-X rotating anode generator
and processed using HKL3000 (Minor et al., 2006). The structures were solved
by molecular replacement (using 3F9Ka as a search model; Hare et al., 2009b)
using BALBES (Long et al., 2008) and resulting models were built using COOT
(Emsley et al., 2010) and refined using REFMAC5 (Murshudov et al., 2011; with
anisotropic temperature factors for the monomeric form 4MQ3).
In Vitro Fluorescence IN 30-Processing Assays
Fluorescence based 30-processing IN activity assay was performed as
described (Merkel et al., 2009). The donor DNA used was prepared by anneal-
ing two fragments: 50-TACAAAATTCCATAGCAGT-6FAM and 50-ACTGC
TATGGAATTTTGTA, and the acceptor DNA was annealed from 50-Biotin-
TAT CCG CGA TAA GCT TTA ATG CGG TAG and 50-Biotin-CTACCGCATTA
AAGCTTATCGCGGATA.
Sequence and Structural Analysis
Structure-guided sequence alignment wasmade with PROMALS3D (Pei et al.,
2008) and annotated using ESPript (Gouet et al., 2003). PyMOL Molecular
Graphics System (Schro¨dinger, LLC) was used for preparing structural figures
and for structural superposition (using IN structures with Protein Data Bank
codes 1BL3c [Maignan et al., 1998] or 1BIS [Goldgur et al., 1998] for HIV-1;
3L2V [Hare et al., 2010] for PFV; and 1C1Aa [Yang et al., 2000] for RSV).
Homology modeling was performed using the Swiss Model server (Arnold
et al., 2006). Analysis of interacting interfaces was performed using ePISA
(Krissinel and Henrick, 2007).
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